Sotera Health Co (SHC) · Aug 6, 2026 · Company update

Strong quarter beats consensus; raised outlook, but Nelson Labs remains soft

Strong quarter beats consensus; raised outlook, but Nelson Labs remains soft

The quarter beat the published bar. Revenue reached $321.4 million versus published consensus of roughly $309.7 million, while adjusted EPS was $0.26 versus consensus of $0.24 — a clear beat on both headline measures.

MetricQ2 2026Q2 2025Market expectation
Net revenue$321.4M$294.3M~$309.7M
Adjusted EBITDA$165.7M$150.7M—
Adjusted EBITDA margin51.6%51.2%—
GAAP diluted EPS$0.19$0.03—
Adjusted diluted EPS$0.26$0.20~$0.24

Growth was broad, but not equally healthy. Revenue rose 9.2% year over year and adjusted EBITDA rose 9.9%, with margin expanding modestly to 51.6% (Financial Highlights). Nordion was the standout, growing revenue 15.8% and segment income 19.2%, helped by the timing of Cobalt-60 harvests (Segment results — Nordion). Sterigenics also delivered solid 8.6% revenue growth and 9.6% segment-income growth (Segment results — Sterigenics).

Nelson Labs is the weak spot. Its revenue increased 6.3%, but segment income barely moved, up only 0.6% in the quarter; first-half segment income was down 4.9% despite 2.9% revenue growth (Segment results — Nelson Labs). That suggests pricing, mix, or cost pressure is absorbing much of the division's growth and keeps the quarter from being a clean operational win.

The most important forward signal is the raised outlook. Management said it is raising full-year 2026 guidance after the first-half performance, whereas the prior framework called for $1.233 billion-$1.251 billion of revenue and $632 million-$641 million of adjusted EBITDA. The supplied filing text does not include the revised ranges, so the size of the increase cannot be measured precisely.

Balance-sheet progress adds to the positive read. Net leverage improved to 3.0x from 3.2x at year-end as trailing adjusted EBITDA increased to $621.6 million and net debt declined to $1.878 billion (Net Debt and Net Leverage). Operating cash flow was $117.9 million, although capital expenditures rose to $92.6 million from $51.1 million in the first half (Cash Flow statement), limiting near-term free-cash-flow conversion. Overall, this is a genuine positive surprise: the earnings beat and raised outlook outweigh the softer Nelson Labs trend and heavier investment spending.

Original filing on SEC EDGAR

More Sotera Health Co news

Strong quarter beats consensus; raised outlook, but Nelson Labs remains soft | SHC Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.